CG Oncology, Inc.

CG Oncology, Inc. filed its 10-Q report for the period ending September 30, 2026. The company reported total revenues of $1.604 million for the third quarter, a slight increase year-over-year. However, the net loss widened to $56.891 million from $43.808 million in the same period last year, primarily driven by increased research and development expenses. Total assets grew significantly to $1.047 billion, largely due to an increase in marketable securities, while cash and cash equivalents saw a decrease.

CG Oncology reported a net loss of $79.1 million for Q2 2026, an increase from $41.4 million in Q2 2025, and a net loss of $139.3 million for the six months ended June 30, 2026. Total revenues for Q2 2026 were $1.16 million, up from zero in the prior year, and $2.24 million for the six-month period. The company maintained a strong liquidity position with $1.03 billion in cash, cash equivalents, and marketable securities. A significant legal proceeding against ANI Pharmaceuticals was resolved in the company's favor, eliminating future royalty obligations and damages.

CG Oncology filed an amendment to its prospectus to increase the shares available for sale under its Open Market Sale Agreement by an additional $500.0 million. The company also reported its second quarter 2026 financial results, with a net loss of $79.1 million, compared to $41.4 million in the prior year. R&D expenses rose to $54.7 million, and G&A expenses increased to $29.0 million. CG Oncology highlighted significant progress in clinical trials, including anticipated topline data for PIVOT-006 and expected BLA completion for HR BCG-unresponsive NMIBC in Q4 2026, and noted a cash position of $1.0 billion, sufficient to fund operations through 2029.

CG Oncology announced the publication of positive results from its pivotal Phase 3 BOND-003 Cohort C trial in The Lancet Oncology. The trial evaluated cretostimogene grenadenorepvec monotherapy for high-risk, BCG-unresponsive non-muscle invasive bladder cancer, demonstrating a 75.5% complete response rate and a median duration of response of at least 27.9 months. The therapy also showed favorable safety, high rates of bladder preservation, and meaningful progression-free survival, positioning it as a potential bladder-sparing treatment.

CG Oncology, Inc. announced that its Chairman, President, and CEO, Arthur Kuan, will participate in fireside chat presentations at two upcoming healthcare conferences. He is scheduled to speak at the Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Live audio webcasts and replays will be accessible via the company's investor relations website.

CG Oncology announced the separation of Ambaw Bellete, its President & Chief Operating Officer, effective June 30, 2026. Concurrently, the Board of Directors appointed Arthur Kuan as President, in addition to his other positions, effective May 20, 2026. The company expects to enter into a separation agreement with Mr. Bellete, providing severance benefits as per his employment agreement, and has initiated a search for a Chief Commercial Officer.

CG Oncology announced positive first results from CORE‑008 Cohort CX, a Phase 2 study evaluating cretostimogene grenadenorepvec in combination with gemcitabine for high‑risk non‑muscle invasive bladder cancer. The study showed encouraging high-grade event-free survival (HG-EFS) of 96.0% at 3 months and 89.5% at 6 months. High complete response rates of 85.7% (ITT) and 92.3% (Efficacy Evaluable) were observed, along with a favorable safety profile with no Grade 3 or greater treatment-related adverse events.

CG Oncology, Inc. announced its participation in the American Urological Association (AUA) 2026 Annual Meeting, where it will present the first results from its CORE-008 Cohort CX Phase 2 Trial. This trial evaluates an intravesical combination therapy for High-Risk BCG-Exposed and BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients. The company will have both poster and podium presentations on May 15 and 16, respectively. Additionally, grant recipients of the CG-SUO-CTC NMIBC Research Fellowship will present their research at the SUO 2026 Annual Meeting at the AUA.

CG Oncology reported a net loss of $60.2 million for Q1 2026, widening from $34.5 million in Q1 2025, as total revenues increased significantly to $1.08 million from $52 thousand. The company substantially strengthened its liquidity, raising $391.4 million in net proceeds from a public offering, bringing its cash, cash equivalents, and marketable securities to $1.08 billion. Additionally, the company successfully defended against a lawsuit from ANI Pharmaceuticals, Inc. regarding royalty payments for its product candidate, cretostimogene.

CG Oncology reported a net loss of $60.2 million, or $(0.71) per share, for the first quarter of 2026, compared to a net loss of $34.5 million, or $(0.45) per share, in the prior year. The company announced that BLA completion for HR BCG-unresponsive NMIBC is now expected in the fourth quarter of 2026, following discussions with the FDA. CG Oncology also strengthened its executive team with the appointment of Jim DeTore as Chief Financial Officer in April 2026 and holds approximately $1.1 billion in cash, sufficient to fund operations through 2029.